NanoViricides (NYSE-A:NNVC) has highlighted the strong safety and efficacy of its lead clinical drug candidate NV-387 against coronaviruses.
Animal studies of NV-387 have shown it can be “highly effective” in treating COVID infections.
In one study, intravenous injection of NV-387 led to a 180% improvement in survival compared to just a 50% improvement for anti-coronavirus drug Remdesivir.
NV-387 in two oral formulations, NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, was also evaluated in a Phase 1 human clinical trial.
No subjects dropped out of the trial or reported adverse events, indicating NV-387’s safety and tolerability even at high dosage levels.
NanoViricides (NYSE-A:NNVC) said there is a clear need for a "highly effective and preferably oral drug" against COVID, which has become a biannual affair with new variants leading each wave in the US.
"President Joe Biden has thankfully recovered from the bout of COVID caused by a new variant," NanoViricides CEO Dr Anil Diwan commented.
"This again brings into limelight the lack of strong drugs against COVID; a gap that NV-387 is expected to fulfill."
Further, NanoViricides has found that its lead drug candidate has a very wide antiviral spectrum, also covering RSV, influenza, and poxviruses.
The company is currently seeking strategic partnerships with pharmaceutical companies to advance NV-387 toward regulatory approvals for multiple antiviral indications.